you mentioned some of those within our oncology business led by keytruda, grew 22% in the quarter. vaccines led by gardasil grew 68% in the quarter and then obviously animal health business, strong growth at 16% we are seeing impact of the pandemic largely receding, and really have strong underlying demand and good momentum in the business right now that i feel really good about. >> so you didn't include mulnupur but striking deal with governments. how do you look at the impact of that drug and dynamics of covid right now. numbers are high but coming down ho are you looking at that for the rest of the year and into early next year? >> yeah. you know, obviously, as you mentioned, while it does seem some numbers around covid-19 are improving, it still is having a grievous impact globally we really do believe that this new anti-viral drug will make a meaningful difference and as we look at the opportunity for it, truly it is about a drug you can take, a pill, anti-viral pill, you can take at home still has, i think, a meaningful tu opportunity as another tool to make a difference. rig